Obesity And Diabetes
- All
- News
- Videos
- Web Stories
-
Obesity, Diabetes And Digital Addiction Rising In India: Economic Survey 2025-26 Healthcare Insights
The Economic Survey 2025-26 flags rising public health threats in India, from obesity, diabetes and other non-communicable diseases to digital addiction and mental health challenges among youth.
-
Can Diabetes And Obesity Drugs Help Treat Psychiatric Disorders?
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving overall health and possibly extending survival in people with serious psychiatric disorders.
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Sugary Drinks, Alcohol Should Be Taxed More To Reduce Non-Communicable Disease Burden: WHO
WHO said consistently low taxes on sugary drinks and alcohol in most countries are fuelling obesity, diabetes, heart disease and cancers.
-
How To Handle Cravings For Junk Food: 10 Tips That Will Actually Help
Studies show that meals rich in protein increase satiety and reduce the urge to snack on calorie-dense, nutrient-poor foods later in the day.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Weight Loss Drugs In India: The Rise Of GLP-1s In 2025
GLP-1 receptor agonists mimic the action of the glucagon-like peptide-1 hormone, which is involved in the regulation of appetite and insulin secretion. When administered, these medications stimulate insulin production.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
San Francisco Sues Oreo, Coca-Cola, KitKat In First-Ever Lawsuit Over Ultra-Processed Foods
The lawsuit links the rise of ultra-processed foods to increasing rates of obesity, diabetes and cancer.
-
Ultra-Processed Food Sales Surge In India, Causing Obesity And Diabetes Crisis: Lancet Study
India is seeing the fastest ultra-processed food (UPF) sales growth, which is surging obesity and diabetes cases, according to The Lancet.
-
Are Halloween Candies Harmful? Risks Every Parent Should Be Aware Of
From excessive sugar, artificial colours and additives, to choking hazards, here are all the risks associated with the candies.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
World Stroke Day 2025: Top 6 Risk Factors That Increase Stroke Chances
This World Stroke Day, experts warn that six key risk factors are driving India's rising stroke burden. Learn how each factor impacts your brain and what you can do
-
Too Many Carbs, Too Little Protein: What The ICMR Study Says About India's Eating Habits
The ICMR findings warn that the imbalance in our diets is directly linked to rising cases of diabetes, prediabetes, and obesity across the country.
-
Obesity, Diabetes And Digital Addiction Rising In India: Economic Survey 2025-26 Healthcare Insights
The Economic Survey 2025-26 flags rising public health threats in India, from obesity, diabetes and other non-communicable diseases to digital addiction and mental health challenges among youth.
-
Can Diabetes And Obesity Drugs Help Treat Psychiatric Disorders?
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving overall health and possibly extending survival in people with serious psychiatric disorders.
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Sugary Drinks, Alcohol Should Be Taxed More To Reduce Non-Communicable Disease Burden: WHO
WHO said consistently low taxes on sugary drinks and alcohol in most countries are fuelling obesity, diabetes, heart disease and cancers.
-
How To Handle Cravings For Junk Food: 10 Tips That Will Actually Help
Studies show that meals rich in protein increase satiety and reduce the urge to snack on calorie-dense, nutrient-poor foods later in the day.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Weight Loss Drugs In India: The Rise Of GLP-1s In 2025
GLP-1 receptor agonists mimic the action of the glucagon-like peptide-1 hormone, which is involved in the regulation of appetite and insulin secretion. When administered, these medications stimulate insulin production.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
San Francisco Sues Oreo, Coca-Cola, KitKat In First-Ever Lawsuit Over Ultra-Processed Foods
The lawsuit links the rise of ultra-processed foods to increasing rates of obesity, diabetes and cancer.
-
Ultra-Processed Food Sales Surge In India, Causing Obesity And Diabetes Crisis: Lancet Study
India is seeing the fastest ultra-processed food (UPF) sales growth, which is surging obesity and diabetes cases, according to The Lancet.
-
Are Halloween Candies Harmful? Risks Every Parent Should Be Aware Of
From excessive sugar, artificial colours and additives, to choking hazards, here are all the risks associated with the candies.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
World Stroke Day 2025: Top 6 Risk Factors That Increase Stroke Chances
This World Stroke Day, experts warn that six key risk factors are driving India's rising stroke burden. Learn how each factor impacts your brain and what you can do
-
Too Many Carbs, Too Little Protein: What The ICMR Study Says About India's Eating Habits
The ICMR findings warn that the imbalance in our diets is directly linked to rising cases of diabetes, prediabetes, and obesity across the country.
